TrialThe Lancet. Oncology2025

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.

Alison C Tree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.